Buloxibutid

Buloxibutid
Clinical data
Other names	VP-01
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name butyl N-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate;
CAS Number	477775-14-7;
PubChem CID	9804984;
DrugBank	DB18038;
ChemSpider	7980744;
UNII	RC2V4W0EYC;
ChEMBL	ChEMBL189568;
Chemical and physical data
Formula	C23H29N3O4S2
Molar mass	475.62 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCOC(=O)NS(=O)(=O)C1=C(C=C(S1)CC(C)C)C2=CC=C(C=C2)CN3C=CN=C3;
	InChI InChI=1S/C23H29N3O4S2/c1-4-5-12-30-23(27)25-32(28,29)22-21(14-20(31-22)13-17(2)3)19-8-6-18(7-9-19)15-26-11-10-24-16-26/h6-11,14,16-17H,4-5,12-13,15H2,1-3H3,(H,25,27); Key:XTEOJPUYZWEXFI-UHFFFAOYSA-N;

Buloxibutid is an investigational new drug that is being evaluated to treat COVID-19 infections.^[1] It is an angiotensin II receptor type 2 agonist.^[2]

References

^ "Buloxibutid - Vicore Pharma". AdisInsight. Springer Nature Switzerland AG.
^ Rein-Hedin E, Sjöberg F, Ganslandt C, Skoog J, Zachrisson H, Bengtsson T, et al. (February 2024). "Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist". Clinical and Translational Science. 17 (2): e13735. doi:10.1111/cts.13735. PMC 10859786. PMID 38344891.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.